Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jenny L. Byrne"'
Autor:
Jesus Duque-Afonso, Jürgen Finke, Myriam Labopin, Charles Craddock, Rachel Protheroe, Panagiotis Kottaridis, Eleni Tholouli, Jenny L. Byrne, Kim Orchard, Urpu Salmenniemi, Inken Hilgendorf, Hannah Hunter, Emma Nicholson, Adrian Bloor, John A. Snowden, Mareike Verbeek, Andrew Clark, Bipin N. Savani, Alexandros Spyridonidis, Arnon Nagler, Mohamad Mohty
Publikováno v:
Bone Marrow Transplantation. 57:1269-1276
In recent years considerable variations in conditioning protocols for allogeneic hematopoietic cell transplantation (allo-HCT) protocols have been introduced for higher efficacy, lower toxicity, and better outcomes. To overcome the limitations of the
Autor:
Mhairi Copland, Daniel Slade, Graham McIlroy, Gillian Horne, Jenny L Byrne, Kate Rothwell, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard E Clark, Matthew L Smith, Rachel Fletcher, Rebecca Bishop, Dragana Milojkovic, Christina Yap
Publikováno v:
The Lancet Haematology. 9:e121-e132
Background: \ud Outcomes for patients with blast-phase chronic myeloid leukaemia are poor. Long-term survival depends on reaching a second chronic phase, followed by allogeneic haematopoietic stem-cell transplantation (HSCT). We investigated whether
Autor:
Stéphane, de Botton, Pau, Montesinos, Andre, Schuh, Cristina, Papayannidis, Paresh, Vyas, Andrew H, Wei, Hans Beier, Ommen, Sergey, Semochkin, Hee-Je, Kim, Richard A, Larson, Jamie, Koprivnikar, Olga, Frankfurt, Felicitas R, Thol, Jörg, Chromik, Jenny L, Byrne, Arnaud, Pigneux, Xavier, Thomas, Olga, Salamero, María-Belén, Vidriales, Vadim A, Doronin, Hartmut, Döhner, Amir T, Fathi, Eric, Laille, Xin, Yu, Maroof, Hasan, Patricia, Martín-Regueira, Courtney D, DiNardo
Publikováno v:
Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 inhibitor, with conventional care regimens (CCR) in patients aged =60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f5721a519b6f1e60c6aafec14ec22139
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16620
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16620
Autor:
Gareth J, Morgan, Faith E, Davies, Walter M, Gregory, Nigel H, Russell, Sue E, Bell, Alexander J, Szubert, Nuria, Navarro Coy, Gordon, Cook, Sylvia, Feyler, Jenny L, Byrne, Huw, Roddie, Claudius, Rudin, Mark T, Drayson, Roger G, Owen, Fiona M, Ross, Graham H, Jackson, J Anthony, Child, A, Smith
Publikováno v:
Blood. 118(5)
As part of the randomized MRC Myeloma IX trial, we compared an attenuated regimen of cyclophosphamide, thalidomide, and dexamethasone (CTDa; n = 426) with melphalan and prednisolone (MP; n = 423) in patients with newly diagnosed multiple myeloma inel
Autor:
Mark W, Drummond, David, Marin, Richard E, Clark, Jenny L, Byrne, Tessa L, Holyoake, Anne, Lennard
Publikováno v:
British journal of haematology. 123(3)
Imatinib mesylate (IM, STI 571, Glivec) can induce a high rate of complete cytogenetic response (CCR) in chronic myeloid leukaemia (CML) patients, although to date the majority of patients continue to have detectable disease by sensitive reverse tran